To start a peptide business legally in 2026, sell peptide therapy as a prescription program rather than selling peptides as products: you own the brand, marketing, and customer relationship, licensed providers prescribe, and a licensed compounding pharmacy dispenses. You do not need a medical license to own that business. This guide covers why the research-use-only route fails, how the prescription model works, what it costs, and the steps to launch.
Which Kind of Peptide Business Are You Starting?
Most people searching for how to start a peptide business picture one of three models. Only one of them is a durable business.
- Selling “research use only” peptides. Vials labeled “for research purposes” or “not for human consumption” are a common starting point, and the most fragile. The FDA has warned companies selling peptides with those labels to consumers for human use, payment processors close the accounts, and ad platforms reject the ads. If you are already selling RUO peptides, see moving from RUO peptides to a telehealth model.
- White-label supplements or cosmetics. Over-the-counter products are legal to sell, but they are not the prescription peptides customers are asking for, and drug claims on them create their own regulatory problems.
- A prescription peptide program. Patients complete an intake, a licensed provider decides whether a peptide is appropriate and prescribes it, and a 503A compounding pharmacy fills the prescription. Only peptides that may legally be compounded are offered. This is the model the rest of this guide covers, and it is how the established direct-to-consumer telehealth brands operate.
Best White Label Telehealth Platform for Peptide Companies
Karpa Health is the white label telehealth platform for peptide companies that want to own the brand and the patient: a 50-state licensed provider network, compounding pharmacy fulfillment from six pharmacy partners, and a branded signup flow and portal, with a published starting price: Launch at $297/mo plus a one-time implementation fee. It fits founders launching a peptide brand. It is not a fit if you want the platform to own your patients.
| Option | What it includes | Best for |
|---|---|---|
| Karpa Health | Own the brand, the patient relationship and the merchant account; 50-state provider network; six pharmacy partners; pricing published from $297/mo with medication at pass-through | Operators who want to keep the patient and set their own prices |
| Your own prescriber and stack | Recruit and credential prescribers, contract the pharmacy, build or buy the software and compliance layer | Practices that already employ prescribers in every state they sell in |
| Revenue-share or referral platform | No infrastructure, but a share of each patient and often the platform owns the relationship | Testing demand before committing to a brand |
| Build the technology yourself | $50,000 to $300,000 of development before the first patient, plus per-state licensing and pharmacy contracting | Teams with a technical team and a long runway |
Program economics at a glance
The numbers below are the ones that decide whether a program is worth running. Every figure is consistent with the platform pricing and the startup cost breakdown.
| Line item | Typical figure |
|---|---|
| Platform fee | from $297 per month |
| Medication cost per patient (pass-through, no markup) | $80 to $150 per month |
| Typical patient price | $350 to $600 per month, premium tiers to $700 |
| Net margin per patient | 50% to 70% |
| Contract prescriber, if you build your own stack instead | $1,500 to $3,000 per month |
| LegitScript certification, if you buy Google or Meta ads | about $3,125 in year one |
| Lean launch capital, platform-based | $5,000 to $25,000 |
| Building the technology yourself | $50,000 to $300,000 before the first patient |
| Time to launch | About 30 days when Karpa builds your website; about 7 days with your own website and LegitScript certification |
| Provider network coverage | all 50 states |
| Compounding pharmacy partners | 6 or more |
What Is a Peptide Telehealth Business?
A peptide company is a telehealth business that markets and manages physician-supervised peptide therapy programs. The company owns the brand, acquires patients, and manages the customer experience. A licensed provider network and a compounding pharmacy handle the clinical and fulfillment layers.
This structure is not unique to peptides. It is the same model used by Hims, Ro, Keeps, and every major direct-to-consumer telehealth brand. The founder or operator owns the commercial layer. Licensed professionals operate the clinical layer.
What a peptide company controls:
- Brand identity, positioning, and audience
- Marketing channels and patient acquisition
- Patient experience and retention programs
- Program offerings and which peptides to lead with
What the platform and provider network handle:
- Patient evaluation and medical history review
- Prescribing decisions and protocol management
- Pharmacy order routing and fulfillment
- HIPAA compliance infrastructure and clinical customer service
Is It Legal to Start a Peptide Company Without a Medical License?
Yes. Operating a peptide telehealth company as a non-licensed entrepreneur is legal when the business is structured correctly.
The regulatory framework distinguishes between operating a healthcare business and providing clinical services. You can own and operate the commercial layer of a telehealth business without a medical license as long as licensed physicians handle all clinical decisions.
The founders and CEOs of Hims & Hers, Teladoc, and Ro are not required to be licensed clinicians. They built commercial platforms. Licensed professionals provide clinical services within those platforms.
The key legal requirements are:
- All prescribing must be done by licensed physicians (handled by your platform)
- Patient evaluations must meet state telehealth standards (handled by your platform)
- HIPAA compliance must be maintained for patient data (handled by your platform)
- Marketing claims must stay within FTC and state advertising guidelines (your responsibility)
Where most non-licensed founders get into trouble is marketing claims - claiming a peptide treats or cures a specific condition crosses from outcomes-based marketing into clinical territory. A good platform provides marketing guidelines to keep you compliant.
What Are the Two Business Models for a Peptide Company?
There are two common paths for launching a peptide company. They share the same clinical infrastructure and differ primarily in how much brand ownership and revenue control you have.
Affiliate - You apply to be an affiliate for a Karpa partner’s existing clinic and refer patients to it. No brand, no operational responsibility, no license, free to apply, and recurring payouts on every patient you refer. This is the lowest-risk entry point and the fastest way to start generating revenue from an existing audience.
Full Clinic - Your own domain, your own brand, your own pricing. Patients never see the platform name. You own the patient relationship and control the entire commercial experience. No medical license required. You pay a platform fee and earn the margin above platform costs, with medication and pharmacy costs passed through at cost and no revenue share. Plans start at $297/mo plus a one-time implementation fee: Launch to validate demand, then Growth and Scale as your patient volume grows. Full long-term brand equity. This is where affiliates land once they have validated their audience.
What Are the Steps to Start a Peptide Company?
Step 1: Choose Your Business Model
Decide which entry point fits your situation. If you have an existing audience and want to test demand immediately without running a clinic, affiliate is the fastest path. If you are building a long-term business and already know the opportunity is real, jump to your own full clinic on the Launch plan, and move to Growth once you are past about 50 patients a month or want more programs.
Most operators who go directly to a full clinic succeed faster because they are all-in on building the brand from day one.
Step 2: Form Your Business Entity
Register an LLC in your home state. A standard single-member or multi-member LLC is sufficient for most operators. You do not need a professional medical corporation - that entity type is for licensed providers running a clinical practice. You are running a commercial technology and marketing business.
Most state LLC formations take 1-3 business days online. Budget for an operating agreement if you have co-founders.
Step 3: Partner With a Telehealth Platform and Provider Network
Your platform is the most important decision you make. It determines your physician coverage, your pharmacy relationships, your compliance infrastructure, and your patient experience.
Key things to evaluate:
- Does the platform cover all 50 states with licensed physicians?
- Which compounding pharmacies are directly integrated?
- Does it support true white-label (your domain, your brand, no platform branding)?
- What does go-live actually look like - days or months?
- Does automated clinical triage reduce time-to-prescribe for patients?
Karpa Health is built specifically for entrepreneurs and clinicians launching peptide, GLP-1, TRT, and hormone programs. Applying to be an affiliate for a Karpa partner’s clinic is free. Full clinic plans start at $297/mo plus a one-time implementation fee, include a dedicated launch team, and go live in about 30 days when Karpa builds your website, or in about 7 days if you already have your own website and LegitScript certification.
Step 4: Build Your Brand Identity
Create your company name, logo, and brand position. Spend time on positioning - your audience and how you speak to them is what differentiates you from every other operator running the same peptides through the same pharmacies.
Strong positioning examples:
- A performance recovery brand for competitive CrossFit athletes
- A longevity brand for executives focused on anti-aging and cognitive performance
- A women’s wellness brand for perimenopause and hormone optimization
- A men’s health brand built around TRT, peptides, and body composition
Your peptide catalog is nearly identical to your competitors’ at launch. Your brand, content, and community are the sustainable competitive advantage.
Step 5: Configure Patient Intake and Clinical Workflows
Work with your platform to configure patient intake forms for each program you are launching. Most platforms provide pre-built clinical questionnaires for each peptide program - you customize the surrounding messaging and brand experience.
Set up your automated follow-up sequences. Patient retention in peptide programs is directly tied to consistent follow-up communication. Programs with active SMS or email follow-up retain patients at significantly higher rates than programs where patients hear nothing after their first prescription fills.
Karpa Health’s automated SMS bot handles patient follow-up automatically, reducing the average time to patient response from over 100 minutes to near-instant - a key driver of retention.
Step 6: Select Your Compounding Pharmacy Partner
Your platform’s pharmacy integration determines your formulary, your pricing, and your supply chain stability. Verify that the platform works with a licensed compounding pharmacy that carries the peptides you plan to offer.
Karpa routes every prescription to its licensed compounding pharmacy partners automatically, with direct-to-patient fulfillment.
Direct integration means prescriptions route automatically after physician approval - no phone calls, no fax, no manual order entry.
Step 7: Launch Marketing and Acquire Your First Patients
With your brand, platform, and intake flow in place, the only remaining variable is patient acquisition.
Channels that work well for peptide companies:
- Content marketing - educational content about specific peptides, outcomes, and protocols builds trust before someone is ready to enroll
- Paid social - Meta and TikTok both allow physician-supervised wellness advertising within compliance guardrails
- Email and community - if you already have a list or community, a direct launch email is typically your highest-converting channel
- Referrals - enrolled patients who see real results become your best acquisition channel; build a referral incentive into your program
Founders who launch to an existing audience of 500 to 5,000 engaged followers typically enroll their first patients within two to four weeks. Founders starting from scratch should expect a 4-6 month runway to meaningful patient volume as organic content builds.
What Peptides Should You Offer First?
Most new peptide companies launch with two to three programs and expand from there. Start with compounds that are currently available for compounding with a valid physician prescription.
| Compound | Primary Use Case | Best Audience Fit |
|---|---|---|
| Sermorelin | Growth hormone stimulation, body composition, sleep quality | Adults 35+ focused on anti-aging, performance, and recovery |
| Glutathione | Antioxidant support, detoxification, skin brightening | Wellness-focused adults, anti-aging and aesthetic audiences |
| NAD+ | Cellular energy, cognitive function, longevity | Executives, biohackers, adults focused on longevity and performance |
GLP-1 medications (semaglutide, tirzepatide) are the highest-demand programs overall, but have more regulatory complexity post-shortage. They are worth adding once your platform relationship and patient acquisition are established.
How Long Until a Peptide Company Is Profitable?
Timeline to profitability is almost entirely a function of audience size at launch.
Existing audience of 500-5,000 engaged followers: Most operators reach profitability within 60-90 days. First patients come from direct outreach to an audience that already trusts you. The clinical outcomes keep them enrolled month after month.
Starting with no existing audience: Plan for a 4-6 month investment period as content marketing, SEO, and paid acquisition build a patient pipeline. The revenue model is recurring - early investment in audience building compounds significantly over time.
Affiliate with an active audience: Can generate first referral revenue within days of launch.
The recurring nature of peptide programs is the key economic driver. A patient on a monthly Sermorelin or GLP-1 protocol who renews for 12 months has dramatically higher lifetime value than a one-time supplement purchase. Patient retention, driven by clinical outcomes and consistent follow-up, is the primary lever for compounding growth.
What Is the Regulatory Landscape for Peptides in 2026?
In February 2026, HHS Secretary RFK Jr. announced that approximately 14 peptides then classified as FDA Category 2 could be moved to Category 1. The announcement did not make them eligible. In April 2026 FDA removed several from Category 2 after their nominations were withdrawn, but none was added to Category 1 or the 503A bulks list, so they still cannot be compounded.
Those peptides include BPC-157, TB-500, CJC-1295, and Ipamorelin, and Karpa does not offer them. Build your program on the compounds that are available today. See the peptide programs page for what is offered.
A compliant telehealth platform monitors regulatory status for each compound in your formulary and updates protocols as rules change. This is one of the most important reasons to work with a dedicated platform rather than building your own stack.
Ready to Start Your Peptide Company?
The infrastructure exists. The demand is already there.
The fastest path from zero to first patients is a turnkey platform that handles the clinical, pharmacy, and compliance layers while you own the brand and patient relationships.
Karpa Health is purpose-built for entrepreneurs and clinicians launching peptide programs in all 50 states. Start as an affiliate for a partner’s clinic, graduate to your own full clinic on the Launch plan, and move up to Growth and Scale as you grow - all on the same infrastructure.
Book a call to see how it works
Sources
- HHS telehealth policy - federal telemedicine rules, including the controlled-substance flexibilities extended through December 31, 2026.
- Center for Connected Health Policy - state-by-state licensure, modality and consent rules, including the rule that a provider must be licensed where the patient is located.
- Federation of State Medical Boards - the corporate practice of medicine doctrine behind the MSO structure non-clinician owners use.
- FDA human drug compounding - why compounded peptides and GLP-1s are not FDA-approved finished drug products.
- LegitScript - the certification Google and Meta require before advertising prescription-adjacent services.
